Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. - Test2 - elhamkhani - TriplyDB

Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.

Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.

http://www.wikidata.org/entity/Q37211043

about

Nitric oxide synthase derangements and hypertension in kidney disease Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.Kidney dysfunction in patients with pulmonary arterial hypertension NADPH oxidase-derived reactive oxygen species contribute to impaired cutaneous microvascular function in chronic kidney disease.Ascorbic acid or L-arginine improves cutaneous microvascular function in chronic kidney disease.Asymmetric dimethylarginine, race, and mortality in hemodialysis patients.Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT).Peripheral vascular dysfunction in chronic kidney disease Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Studies Cardiovascular risk is similar in patients with glomerulonephritis compared to other types of chronic kidney disease: a matched cohort study.eNOS Glu298Asp Polymorphism and Endothelial Dysfunction in Patients with and without End-stage Renal Disease.ADMA predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus undergoing coronary angiography Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators?Asymmetric dimethylarginine and all-cause mortality: a systematic review and meta-analysis.The role of asymmetric and symmetric dimethylarginines in renal disease.Role of asymmetrical dimethylarginine in the progression of renal disease.The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis.Asymmetric dimethylarginine, endothelial dysfunction and renal disease Asymmetric dimethylarginine (ADMA) treatment induces apoptosis in cultured rat mesangial cells via endoplasmic reticulum stress activation.Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort.Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms.Metabolomic Profiling of Arginine Metabolome Links Altered Methylation to Chronic Kidney Disease Accelerated Atherosclerosis.The role of the DDAH-ADMA pathway in the protective effect of resveratrol analog BTM-0512 on gastric mucosal injury.Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.Chronic kidney disease and subclinical lacunar infarction are independently associated with frontal lobe dysfunction in community-dwelling elderly subjects: the Sefuri brain MRI study.Carotid Plaque Score and Risk of Cardiovascular Mortality in the Oldest Old: Results from the TOOTH Study.Differences in plasma metabolomics between sows fed DL-methionine and its hydroxy analogue reveal a strong association of milk composition and neonatal growth with maternal methionine nutrition.Uremic Toxin Clearance and Cardiovascular Toxicities.

P2860

Q26849234-D7AC6924-062D-41B1-9D2B-6D72E040F8AF Q28087272-0BD89632-E8B7-4811-A7E8-463F1CCB7AB9 Q30300218-080090C2-E412-490A-B299-E8D2F326D96E Q33738621-1FE74736-B652-4E1C-A2A5-32EED556C51E Q33764561-08E8E6B8-E16D-447B-B44D-949982915BBF Q34008329-F026A244-A8D4-47CF-9B12-57AFC23C62DB Q34008883-E81A3EF0-F47C-4F0B-AF3D-DE00944D83B9 Q34768530-C41661C0-E116-43AC-B998-3527E6E28CBC Q35012914-7D50F2B6-48EF-4936-BAF4-49430F4A0B24 Q36182184-125E4203-BCCD-433A-8AAF-48D302F22277 Q36315383-52E15E26-E037-4258-A48A-1AD49B7C8958 Q37047148-4C278AED-8B48-4E1E-8C8A-46D98A9764F4 Q37646687-E49B1911-A524-47C6-BDF8-D5A865E847B9 Q37684919-4599C3C2-C8B9-4E39-B268-ED8389B8E103 Q37704715-9893CFE8-3C0D-4F25-B1B3-A3A04DCFE0EA Q37858880-0FE7495F-2F71-492E-B424-49DEADDDC2D8 Q38046935-97B4F2C5-47EA-4EDE-9022-8A5A3372F0E0 Q38055449-008C0E61-2FD0-4CAC-B8D8-1CD8548F172B Q38056493-AC6E1B70-F8B0-46B9-956A-F4CFB7F2F9B9 Q38785054-69F18C0C-BDF2-4003-BBC5-33B686B06C39 Q40160323-91803B7F-1637-4FF7-AFDC-5BA20132F0B1 Q41573480-A40E3747-C61F-44F0-B842-27D5CB8536EF Q41979223-97846026-0B93-455E-B943-4168616E4CF9 Q43016211-1686336F-FD13-439E-A09C-9C639BEB260E Q47860627-1E5897B7-D564-48B4-9E1D-2D85DC0F95E9 Q49136847-70C46356-B3E9-45D6-9D04-F80C1092D5DD Q50255281-7D5EE4CE-7BFA-4BFE-975C-E02CC84E3A53 Q50603566-76A5B7A2-4061-4707-A536-B4F2055A79F4 Q55473173-AC9B3738-8EA9-4A36-B8C1-929EAD3FC6D6

P2860

Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.

http://www.wikidata.org/entity/Q37211043

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.

@en

Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.

@nl

type

label

Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.

@en

Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.

@nl

prefLabel

Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.

@en

Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.

@nl

P1433

Q37211043-B6DE4F0A-1D03-45E6-841B-098A9099A269

P1476

Q37211043-735F26F0-731A-4E4A-A682-FC7BF0066DAA

P2093

Q37211043-038C8DDA-D74D-40C1-95B9-D285E14EFAD3

Q37211043-2F20DE2A-FCEF-495B-9B28-A8C2EC0C65DF

Q37211043-4FFE4B48-B061-4B3F-8EF2-EFA0F6D92224

Q37211043-59BF281C-3F12-4BDD-8A84-9B21B07EA5F2

Q37211043-867264ED-2057-4338-8E59-5B8C65D10284

Q37211043-A9A854E6-D9FF-416A-B72C-D43768D8E715

Q37211043-CC0A5E1C-330C-44CA-8A26-5E2360BBAF10

Q37211043-CDD1F5BC-E1FB-48C1-A5F7-96A0D40B04B5

Q37211043-EF3C247D-87E7-45B9-9A2E-AF233FFAE163

P2860

Q37211043-079AEED4-DC2B-4956-806A-F52762128194

Q37211043-0EF02FCA-DC1F-4988-BB88-5F3EAFABECE0

Q37211043-1A3181FB-69B6-4880-ADA9-EB9D8256F87A

Q37211043-2037EFC7-35C5-4EB7-8932-8A740FC0A20F

Q37211043-2305C5E3-367D-4ACE-87DF-F4B5325063DC

Q37211043-2A282F31-918D-4899-A7DB-8EAF782D8340

Q37211043-2F0054A5-6E4E-4463-BB96-024D44ACE675

Q37211043-34163433-191A-4D95-A517-8FB14C223F06

Q37211043-34709C2B-A5C5-4B38-96D0-8D674154EC7C

Q37211043-467D130F-4E3F-477D-8809-67CBDF7EF533

P304

Q37211043-D26CCE19-31A8-4723-8A6A-49F75F1CB75B

P31

Q37211043-5D48011B-BC01-4542-A0BA-98D4D756AA98

P356

Q37211043-D837F250-8570-4E8B-ADC7-43A26FA2A352

P433

Q37211043-C4D5B7BF-776F-494D-BBD6-79B8F64578C7

P478

Q37211043-113B90BF-F853-475A-BC73-C8FC6372A307

P577

Q37211043-5B8A48D7-C2B3-4EAD-A130-38BD69282F80

P5875

Q37211043-B86A77A4-11DE-4D74-A487-7201869467AE

P698

Q37211043-FAFB9410-40C2-4DA3-9476-738129B60498

P932

Q37211043-63CFC81E-8787-49ED-84C2-F02A9A0F8763

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.

@en

P2093

Allan J Collins

http://www.w3.org/2001/XMLSchema#string

Gerald J Beck

http://www.w3.org/2001/XMLSchema#string

Jill Melendez Young

http://www.w3.org/2001/XMLSchema#string

John W Kusek

http://www.w3.org/2001/XMLSchema#string

Mark J Sarnak

http://www.w3.org/2001/XMLSchema#string

Norma Terrin

http://www.w3.org/2001/XMLSchema#string

Tom Greene

http://www.w3.org/2001/XMLSchema#string

Vandana Menon

http://www.w3.org/2001/XMLSchema#string

Xuelei Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Endothelial dysfunction: a comprehensive appraisal.

Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension

Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis.

Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study.

Epidemiology of cardiovascular disease in chronic renal disease.

Endothelial function. From vascular biology to clinical applications.

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.

Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg.

Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

P304

1115-1120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.06671208

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24355306

http://www.w3.org/2001/XMLSchema#string

P698

19389824

http://www.w3.org/2001/XMLSchema#string

P932

2689879

http://www.w3.org/2001/XMLSchema#string